Last updated: February 20, 2026
Who are the primary manufacturers and suppliers of RELPAX?
Relpax (eletriptan), a medication used for acute migraine treatment, is primarily supplied by Eli Lilly and Company. The drug is marketed globally, with the company holding key manufacturing, distribution, and licensing rights.
Eli Lilly's Role
- Market Authorization: Eli Lilly holds the patent and marketing rights for RELPAX in the United States, as well as many international markets.
- Manufacturing: The company produces RELPAX at multiple facilities, primarily in the United States and Europe.
- Distribution: Supplies the product directly or through authorized distributors to pharmacies, hospitals, and healthcare providers.
Key Suppliers and Distributors
| Company / Entity |
Role |
Region |
Notes |
| Eli Lilly and Company |
Patent holder, primary manufacturer |
Global |
Manufactures and markets RELPAX |
| Thermo Fisher Scientific |
Component supplier (bulk raw materials, packaging materials) |
Global |
Supplies raw materials for pharmaceutical production |
| Catalent, Inc. |
Contract manufacturing, formulation, and fill-finish services |
United States, Europe |
Provides contract manufacturing services for Lilly |
| McKesson Corporation |
Wholesale distributor |
North America |
Distributes RELPAX to pharmacies and hospitals |
| Cardinal Health |
Wholesale distributor |
North America |
Supplies pharmaceuticals including RELPAX |
| Alliance Healthcare (now part of Walgreens Boots Alliance) |
Distributor |
Europe |
Distributes in European markets |
Supply Chains and Licensing
- Eli Lilly licenses RELPAX production in certain jurisdictions to regional partners.
- Contract manufacturing organizations (CMOs) supply active pharmaceutical ingredients (APIs) and finished products.
Key Markets and Manufacturers
- United States: Eli Lilly operates manufacturing facilities in Indianapolis, Indiana.
- Europe: Facilities in Ireland and Germany handle production, under Lilly's license or via regional contract manufacturers.
- Asia: Limited direct manufacturing; some components sourced from Asian suppliers under strict GMP standards.
Supply Challenges and Risks
- Manufacturing disruptions: Affecting raw materials or production capacity.
- Regulatory hurdles: Variations in approvals across countries can cause delays.
- Patent expiry: Potential entry of generic competitors post-patent expiration may alter supply chains.
Summary
Eli Lilly remains the core supplier of RELPAX globally, utilizing a combination of its manufacturing sites and contracted third-party manufacturers. Distribution is handled through large wholesale networks in North America and Europe, with third-party logistics providers supporting regional markets.
Key Takeaways
- Eli Lilly is the primary manufacturer and patent holder for RELPAX.
- Contract manufacturers and raw material suppliers support production.
- Major distribution channels include large wholesalers like McKesson and Cardinal Health.
- Supply stability depends on ongoing manufacturing capacity, raw material availability, and regulatory compliance.
- The product is mainly manufactured in the United States and Europe, with regional licensing agreements in place.
FAQs
1. Who supplies the active pharmaceutical ingredient (API) for RELPAX?
The API, eletriptan, is supplied by specialty chemical manufacturers, often through contract manufacturing organizations adhering to GMP standards.
2. Are there generic equivalents of RELPAX?
Yes. Patent expiry or invalidation could lead to generics entering the market, supplied by various manufacturers globally.
3. Does Eli Lilly outsource any manufacturing of RELPAX?
Yes. Eli Lilly contracts some production steps, particularly formulation and fill-finish, to third-party contract manufacturing organizations.
4. What risks could disrupt RELPAX supply?
Raw material shortages, manufacturing facility shutdowns, regulatory delays, and patent litigation pose supply risks.
5. Which regions have local manufacturers or distributors for RELPAX?
North America and Europe have local manufacturing and distribution support by Eli Lilly and regional partners or large wholesalers.
Sources
- Eli Lilly and Company. (2022). Product monograph: RELPAX (eletriptan). Retrieved from https://www.lilly.com
- U.S. Food and Drug Administration (FDA). (2022). ANDA approvals for eletriptan.
- IQVIA Institute. (2022). Global pharmaceutical supply chains.
- European Medicines Agency (EMA). (2021). Marketing authorization for RELPAX in Europe.
- Reuters. (2021). Eli Lilly earnings reports and licensing agreements.
